Login
Super Investors GENERAL ATLANTIC, L.P.
GA

GENERAL ATLANTIC, L.P.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$2.48B
Positions
12
Quarter ended
September 30, 2026
Filed
November 13, 2026

Reported portfolio value by quarter (54 quarters reported)

$17.1B $959M
Q2 13 Q1 16 Q4 18 Q3 21 Q2 24 Q3 26

$959M in Q2 2013 → $2.48B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Dlocal 20.4% Trimmed 21% 36,814,136 $507M
C Chime 20.3% Trimmed 11% 18,926,627 $504M
LM Liftoff Mobile 16.1% Unchanged 25,315,646 $400M
Xp, Inc 15.2% Trimmed 13% 17,958,953 $377M
A Alkami 10.7% Unchanged 19,379,038 $265M
Seaport Therapeutics 5.0% Unchanged 6,101,582 $123M
Riskified 3.4% Added 100% 10,649,996 $84.2M
Nurix Therapeutics 2.9% Unchanged 3,032,185 $71.9M
P Pharvaris 2.1% Trimmed 75% 1,651,490 $52.4M
PM Parabilis Medicines 2.0% Unchanged 1,538,461 $49.7M
K Korsana 1.8% New 1,366,242 $43.7M
GC Grove Collaborative 0.1% Unchanged 2,474,859 $2.62M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 13, 2026

Company Action Shares changed Value of change % of portfolio
P Pharvaris Trimmed −4,899,267 −$155M 2.1%
Dlocal Trimmed −9,842,559 −$135M 20.4%
Revolution Medicines Exited −357,791 −$67M —
C Chime Trimmed −2,333,056 −$62.2M 20.3%
Xp, Inc Trimmed −2,607,180 −$54.7M 15.2%
K Korsana New +1,366,242 +$43.7M 1.8%
Riskified Added +5,324,998 +$42.1M 3.4%

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
LM Liftoff Mobile New +25,315,646 +$608M 20.9%
Seaport Therapeutics New +6,101,582 +$133M 4.6%
European Wax Center Exited −13,110,492 −$75.8M —
A Alkami Added +4,041,543 +$73.2M 12.1%
Revolution Medicines Trimmed −350,000 −$65.5M 2.3%
Centessa Pharmaceuticals Exited −1,354,830 −$53.8M —
P Pharvaris Trimmed −1,480,495 −$51.2M 7.8%
PM Parabilis Medicines New +1,538,461 +$42.1M 1.4%
Nurix Therapeutics Trimmed −1,069,680 −$26M 2.5%
Webull Exited −50,816 −$244K —

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Alignment Healthcare Exited −13,167,733 −$260M —
Revolution Medicines Trimmed −2,105,137 −$205M 3.2%
Centessa Pharmaceuticals Trimmed −4,762,885 −$189M 2.5%
A Alkami Added +3,346,015 +$52.4M 11.2%
Xp, Inc Trimmed −2,133,000 −$40.6M 18.2%
Nurix Therapeutics Trimmed −795,294 −$12.3M 3.0%

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Akero Therapeutics Exited −5,733,989 −$272M —
Alignment Healthcare Trimmed −11,119,494 −$220M 9.1%
Nurix Therapeutics New +4,897,159 +$92.9M 3.2%
Centessa Pharmaceuticals Trimmed −3,564,103 −$89.1M 5.3%
Webull Trimmed −7,148,051 −$55.5M —
Royalty Pharma Exited −1,500,000 −$52.9M —
C Chime Added +2,050,923 +$51.6M 18.6%
Xp, Inc Trimmed −2,818,600 −$46.1M 12.9%
Revolution Medicines Added +338,500 +$27M 7.8%
Adagene Exited −3,782,339 −$7.53M —

Showing the 10 largest of 11 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 13, 2025

Company Action Shares changed Value of change % of portfolio
Alignment Healthcare Trimmed −19,706,096 −$344M 12.7%
Dlocal Trimmed −17,250,000 −$246M 20.0%
Revolution Medicines New +2,474,428 +$116M 3.5%
A Alkami Added +2,346,162 +$58.3M 8.9%
P Pharvaris Added +500,000 +$12.5M 6.0%
Webull Added +50,816 +$752K 3.2%
Adagene Trimmed −43,613 −$86.8K 0.2%

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
C Chime New +19,208,760 +$663M 18.3%
Alignment Healthcare Trimmed −17,000,000 −$238M 17.0%
Webull New +7,148,051 +$85.5M 2.4%
Xp, Inc Trimmed −4,100,000 −$82.8M 14.2%
I Immunocore Exited −1,261,684 −$37.4M —
Akero Therapeutics Added +500,000 +$26.7M 8.4%
Acelyrin Exited −2,695,327 −$6.66M —
W Wish Exited −609,616 −$4.26M —
Alumis New +1,297,530 +$3.89M 0.1%

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

Company Action Shares changed Value of change % of portfolio
Third Harmonic Bio Exited −3,372,323 −$34.7M —

Q4 2024

quarter ended December 31, 2024 · filed February 07, 2025

Company Action Shares changed Value of change % of portfolio
Squarespace Exited −10,611,073 −$493M —
A Alkami Trimmed −5,875,000 −$215M 12.6%
Blend Labs Exited −19,132,440 −$71.7M —
Adagene Added +3,561,952 +$7.09M 0.3%
Third Harmonic Bio Added +413,561 +$4.26M 1.2%
GC Grove Collaborative Added +1,538,839 +$2.14M 0.1%
Acelyrin Trimmed −194,341 −$610K 0.3%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support